Business, energy, technology, markets and global industry news from Business News Today

nogapendekin alfa inbakicept-pmln

PharmaDeviceNews nogapendekin alfa inbakicept-pmln
Representative image of an oncology researcher reviewing bladder cancer treatment data, as ImmunityBio’s ANKTIVA plus BCG analysis raises new questions about cost, response durability and bladder-sparing care in BCG-unresponsive NMIBC.
Pharma & Biotech

Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Read More
Pharma & Biotech

Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise

ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.

Read More